A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Unexpected adverse events were observed in a subset of patients on drug. In an over abundance of caution the study was terminated. All adverse events resolved with no sequelae.

Conditions

Dry Eye Syndromes

Interventions

DRUG: IC265 Ophthalmic Solution 1%
DRUG: Placebo Ophthalmic Solution (Vehicle)

Sponsor

Iacta Pharmaceuticals